Thomas Shrader
Stock Analyst at BTIG
(1.51)
# 3,345
Out of 4,944 analysts
49
Total ratings
36.59%
Success rate
-7.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Downgrades: Neutral | n/a | $105.20 | - | 4 | Jul 10, 2025 | |
| INMB INmune Bio | Downgrades: Neutral | n/a | $2.56 | - | 3 | Jul 1, 2025 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $5.37 | +67.60% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $0.86 | +366.20% | 3 | Mar 24, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $31.55 | +407.13% | 4 | Feb 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $19.21 | +113.43% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $2.18 | +129.36% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.39 | - | 3 | Sep 4, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.20 | +263.64% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.70 | +1,042.86% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.69 | +1,179.32% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $14.39 | +66.78% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $2.60 | +169.23% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.20 | +141.94% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.39 | +3,212.95% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.55 | +545.16% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.27 | +1,632.28% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.60 | +3,087.50% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.61 | +513.03% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.81 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $9.14 | +534.57% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.43 | +109.79% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $135.19 | +155.94% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.54 | - | 1 | Jun 30, 2017 |
Verona Pharma
Jul 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $105.20
Upside: -
INmune Bio
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.37
Upside: +67.60%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.86
Upside: +366.20%
Vaxcyte
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $31.55
Upside: +407.13%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $19.21
Upside: +113.43%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $2.18
Upside: +129.36%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.20
Upside: +263.64%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.70
Upside: +1,042.86%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.69
Upside: +1,179.32%
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $14.39
Upside: +66.78%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.60
Upside: +169.23%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.20
Upside: +141.94%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.39
Upside: +3,212.95%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.55
Upside: +545.16%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.27
Upside: +1,632.28%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.60
Upside: +3,087.50%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.61
Upside: +513.03%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.81
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $9.14
Upside: +534.57%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $135.19
Upside: +155.94%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.54
Upside: -